Impact of etanercept on the costs of rheumatoid arthritis (RA): Results from a French observational study - 10/01/08
Corresponding author.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Introduction |
Economical impact of rheumatoid arthritis (RA) has been widely modified thanks to TNF inhibitors. Our study aims to estimate the impact etanercept prescription, in term of health resources consumption, within a regional cohort of French RA patients.
Methods |
The study included 148 RA patients, with a mean follow-up duration of 343 days before and after etanercept initiation. Data were anonymously collected from ERASME database of French Health Insurance in Midi-Pyrénées region. A patient-by-patient microcosting approach was performed.
Results |
The average annual cost per patient, attributable to RA, was 2.8 times higher after treatment by etanercept than before (15,148.57€ versus 5248.95€). We observed a rise in pharmaceutical costs, from 11.7% of direct medical costs before to 69.7% after etanercept initiation (120.12€ versus 9995.23€). We observed a small decrease particularly for NSAIDs (142.14€ versus 102.21€) and physiotherapy (286.40€ versus 138.77€). Attributable act costs and indirect costs did not differ before and after etanercept initiation.
Discussion |
In this short-term study, initiation of etanercept in RA patients did not come along with a decrease of consumption of health resources. Long-term studies are needed to reveal a potential economical advantage as a consequence of the clinical, structural and functional efficacy of anti-TNF.
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, Cost of illness, TNF inhibitors
Plan
Vol 75 - N° 1
P. 25-28 - janvier 2008 Retour au numéro
Article précédent
- Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis
- Martin Soubrier, Pierre Jouanel, Sylvain Mathieu, David Poujol, Delphine Claus, Jean Jacques Dubost, Jean Michel Ristori
- Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs
- Antonio Spadaro, Tania De Luca, Maria Pia Massimiani, Fulvia Ceccarelli, Valeria Riccieri, Guido Valesini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?